A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
Public ClinicalTrials.gov record NCT01944839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
Study identification
- NCT ID
- NCT01944839
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 619 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2013 (Type not available)
- Primary completion
- Dec 2016 (Actual)
- Completion
- Dec 2016 (Actual)
- Last update posted
- Oct 30, 2024
2013 – 2016
United States locations
- U.S. sites
- 50
- U.S. states
- 30
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | 85014 | — |
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Beverly Hills | California | 90211 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | San Francisco | California | 94107 | — |
| Not listed | Santa Barbara | California | 93103 | — |
| Not listed | Colorado Springs | Colorado | 80909 | — |
| Not listed | Bridgeport | Connecticut | 06606 | — |
| Not listed | New London | Connecticut | 06320 | — |
| Not listed | Altamonte Springs | Florida | 32701 | — |
| Not listed | Fort Myers | Florida | 33907 | — |
| Not listed | Sarasota | Florida | 34233 | — |
| Not listed | Tampa | Florida | 33609 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Winter Haven | Florida | 33880 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Springfield | Illinois | 62704-2173 | — |
| Not listed | Indianapolis | Indiana | 46290 | — |
| Not listed | Leawood | Kansas | 66211 | — |
| Not listed | Lexington | Kentucky | 40509 | — |
| Not listed | Lexington | Kentucky | 40536 | — |
| Not listed | Louisville | Kentucky | 40202 | — |
| Not listed | New Orleans | Louisiana | 70121 | — |
| Not listed | Chevy Chase | Maryland | 20815 | — |
| Not listed | Boston | Massachusetts | 02111 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Jackson | Michigan | 49202 | — |
| Not listed | Southfield | Michigan | 48034 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | St Louis | Missouri | 63110 | — |
| Not listed | Las Vegas | Nevada | 89135 | — |
| Not listed | Portsmouth | New Hampshire | 03801 | — |
| Not listed | Northfield | New Jersey | 08225 | — |
| Not listed | Albuquerque | New Mexico | 87109 | — |
| Not listed | Great Neck | New York | 11021 | — |
| Not listed | Shirley | New York | 11967 | — |
| Not listed | Cincinnati | Ohio | 45242 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Ashland | Oregon | 97520 | — |
| Not listed | Camp Hill | Pennsylvania | 17011 | — |
| Not listed | Philadelphia | Pennsylvania | 19107 | — |
| Not listed | Pittsburgh | Pennsylvania | 15212 | — |
| Not listed | Ladson | South Carolina | 29456 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | Abilene | Texas | 79606 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Tyler | Texas | 75701 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
| Not listed | Fairfax | Virginia | 22031 | — |
| Not listed | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01944839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2024 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01944839 live on ClinicalTrials.gov.